Testing effectiveness (Phase 2)Ended earlyNCT00385827
What this trial is testing
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Who this might be right for
Cancer, Prostate
Centocor, Inc. 106